Rhabdomyosarcoma of the Breast in Adolescent and Young Adult (AYA) WomenAudino, Anthony N. MD; Setty, Bhuvana A. MD; Yeager, Nicholas D. MDJournal of Pediatric Hematology/Oncology: January 2017 - Volume 39 - Issue 1 - p 62–66 doi: 10.1097/MPH.0000000000000710 Clinical and Laboratory Observations Buy Abstract Author InformationAuthors Article MetricsMetrics Soft tissue sarcoma constitutes 8% of all tumors in adolescent and young adults (AYA), with rhabdomyosarcoma (RMS) accounting for 5.2% to 6.5% of the soft tissue sarcoma total within this group. AYAs have a higher propensity for metastasis and inferior outcomes. Metastases to the breast have been reported in ∼3% to 6% of RMS cases. A review of our hospital’s tumor registry identified cases of RMS diagnosed between January 1, 2004 and December 31, 2013. A total of 46 patients with RMS were identified, having a mean age of 12.5 years (range, 1 to 49 y). There were 26 males (57%) and 20 females (43%). Eighteen patients (39%) were AYAs, including 10 women. Four patients (8.7%) were identified with breast involvement, all of whom were AYA females. Treatment modalities included chemotherapy, surgical resection, and radiation. One patient is a long-term survivor. Although RMS is uncommon in AYAs, breast involvement occurs almost exclusively in AYA women and is associated with alveolar histology, metastatic disease, and poor outcomes. In total, 4/10 of all AYA females had breast involvement. Routine examination or imaging of the breasts in AYAs with RMS is not currently standard practice at diagnosis or follow-up, but this analysis suggests it should be considered in female AYA patients. *Division of Pediatric Hematology/Oncology, Nationwide Children’s Hospital †Department of Pediatrics, the Ohio State University, Columbus, OH The authors declare no conflict of interest. Reprints: Anthony N. Audino, MD, Pediatric Hematology/Oncology, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH, 43205 (e-mail: firstname.lastname@example.org). Received July 15, 2015 Accepted October 19, 2016 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.